tirzepatide problems Efficacy and Safety of in Adults with Obesity or Overweight Published July 21, 2022 N Engl J Med 2022;387:205–216 🔹 Background Obesity and overweight remain major global health associated with FDA Approves Lilly's Zepbound™ (tirzepatide)

Even at lower doses, GLP-1 receptor agonists may provide powerful health benefits

Most patients refrigerate their in-use pen between injections to minimize degradation and reduce injection-site reactions caused by warmer medication

"Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease"

GLP-1 medications may need to be paused before surgery due to gastroparesis and aspiration risk

As there was clear evidence of clinically significant weight loss from the Phase III trials, tirzepatide has been planned to be evaluated as an anti-obesity drug in non-diabetic (SURMOUNT 1 trial), and diabetic (SURMOUNT 2 trial) populations, and on those who are already on intensive lifestyle programmes (SURMOUNT 3 trial)